Abstract: The present invention relates to a breathable insulation, could be set on the some part or whole of fabric, cloth, silk, cotton, textile, satin, yarn, linen, wool, synthetic fiber, rayon, polyester fiber, nylon or integrated with part or all of the fabric, cloth, silk, cotton, textile, satin, yarn, linen, wool, synthetic fiber, rayon, polyester fiber, nylon, comprising one or several support units located in the same plane or in different planes to allow air there in convection, with said design, the support units could form three-dimensional spaces to help air convection and to allow warm air come out of human skin. It helps for air distribution and convection, and helps the temperature of the human skin being warm through, not sultry, and achieves the purpose of natural insulation breathable.

Abstract: This invention relates to DPP-IV inhibitory citrate or tartrate salts of pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that are physically and chemically stable, substantially non-deliquescent solids under ambient conditions.

Abstract: This invention relates to DPP-IV inhibitory citrate or tartrate salts of pyrrolidinylaminoacetyl pyrrolid acid compounds that are physically and chemically stable, substantially non-deliquescent solids under ambient conditions.

Abstract: A dosage form is provided for an anti-diabetic DPP-IV inhibitor of formula (I) as its tartarate salt, wherein the purity of the active pharmaceutical ingredient is maintained over a prolonged storage period under conditions similar to those likely encountered in home storage of the medication by a diabetic patient. A formulation free of calcium salts such as calcium phosphate, but including microcrystalline cellulose, copovidone, crospovidone, colloidal silicon dioxide, and magnesium stearate, when compacted into a tablet with the active pharmaceutical ingredient, was shown to be stable for at least six months at 40° C. and 75% relative humidity. Methods for preparation of the dosage form are also provided.

Abstract: The invention provides a crystalline form of a synthetic intermediate useful in the preparation of a DPP-IV inhibitor, a method for preparing the crystalline form of the intermediate, and a method of using the crystalline form of the intermediate in the preparation of the inhibitor.

Abstract: Methods and intermediates for the synthesis of selective inhibitors of dipeptidyl peptidase IV (DPP-IV) are provided. Coupling of a carboxylate salt with a boro-proline derivative provides a protected form of a DPP-IV inhibitor, which may be deblocked to yield the medicinal compound. The carboxylate salt can be a crystalline form of a sodium salt or a dicyclohexylammonium salt. The inhibitor can be used in the treatment of diabetes.

Abstract: The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.

Abstract: The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.